In 2005, the IDSA and ATS issued guidelines on the treatment of pneumonia in hospitalized patients, and included a new categorization of healthcare-associated pneumonia (HCAP) for patients with recent interface with medical facilities (guidelines). In this prospective cohort, researchers identified 362 patients with CAP, HAP, or HCAP, and determined rates of guideline-appropriate treatment and mortality. Patients with HCAP were much less likely to receive guideline-concordant antibiotics (27%) than patients with CAP (59%) or HAP (69%), and their mortality was much higher (18%) than patients with CAP (7%) (abstract). As a reminder, HCAP patients include: nursing home or long-term care facility residents, anyone hospitalized (2+ days) in the last 90 days, or anyone undergoing hemodialysis / wound care / chemotherapy / IV antibiotics in the last 30 days. These patients should be treated with 2 anti-pseudomonal drugs and 1 anti-MRSA drug (guidelines)
Share This Post
Categories
Related Posts
During the first two to three weeks of the pandemic in 2020, I was involved in a lot of meetings about the current status and future plans for the impending surge of COVID-19 patients we were anticipating. It was during that time we witnessed COVID-19 ravaging cities like New York City. In one of the […]
The COVID-19 pandemic has changed health care as we know it. It has sowed fear and doubt among the public and created endless questions without answers. Our hospitalized patients may wonder why they can’t have their families beside them and worry about contracting the virus in the hospital. Strict visitation policies only add to their […]
This article is part of a series in The Hospital Leader written by members of the Division of Hospital Medicine at Dell Medical School at The University of Texas in Austin, exploring lessons learned from the coronavirus pandemic and outlining an approach for creating COVID-19 Centers of Excellence. During the early months of the COVID-19 […]
Leave A Comment